Archive:
Dec 17, 2024, 12:00 AM
Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047
Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in …